Journal article
Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect study
Abstract
INTRODUCTION: Simoctocog alfa (Nuwiq®) is a 4th generation recombinant FVIII with proven efficacy for the prevention and treatment of bleeding episodes (BEs) in previously treated patients with severe haemophilia A. The NuProtect study assessed the immunogenicity, efficacy and safety of simoctocog alfa in 108 previously untreated patients (PUPs). The incidence of high-titre inhibitors was 16.2% and no patients with non-null F8 mutations …
Authors
Mathias M; Abraham A; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M
Journal
European Journal Of Haematology, Vol. 111, No. 4, pp. 544–552
Publisher
Wiley
Publication Date
October 2023
DOI
10.1111/ejh.14040
ISSN
0902-4441